title: [Toxic hepatitis associated with tamoxifen use. A case report and literature review].
abstract: Tamoxifen is an antiestrogenic drug that acts by binding to the estrogen receptor. The drug is used as a co-adjuvant treatment in advanced breast cancer expressing the oestrogen-receptor protein. Clinical trials of tamoxifen have shown its efficacy in reducing mortality and recurrence rates over a five-year treatment. Cases of tamoxifen-associated hepatotoxicity have been described, including cholestasis with or without cytolysis and steatohepatitis. We report the case of a female patient who developed hepatic alterations while undergoing continuous tamoxifen treatment. We also present an overview of similar cases published to date and comment on the advisability of continuing or suppressing this treatment in patients with hepatotoxicity or after a five-year treatment period.
authors.affiliation: Unidad de Farmacología Clínica, Hospital General Universitario de Alicante, Spain. lasso_mca@gva.es
authors.forename: M C
authors.initials: MC
authors.lastname: Lasso De La Vega
authors.forename: P
authors.initials: P
authors.lastname: Zapater
authors.forename: J
authors.initials: J
authors.lastname: Such
authors.forename: J
authors.initials: J
authors.lastname: Sola-Vera
authors.forename: A
authors.initials: A
authors.lastname: Payá
authors.forename: J F
authors.initials: JF
authors.lastname: Horga
authors.forename: M
authors.initials: M
authors.lastname: Pérez-Mateo
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D013629:Tamoxifen / Q000009:adverse effects*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen